Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDInnate Pharma Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.08 | -$0.08 | -$0.08 |
| Q2 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
Innate Pharma Earnings Date And Information
Innate Pharma last posted its earnings results on Thursday, September 17th, 2026. The company reported $-0.24121 earnings per share for the quarter, topping analysts' consensus estimates of $-0.29458 by $0.05337. The company had revenue of 3.16 M for the quarter and had revenue of 2.79 M for the year. Innate Pharma has generated $-1 earnings per share over the last year ($-0.53 diluted earnings per share) and currently has a price-to-earnings ratio of -3.05. Innate Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Innate Pharma Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/17/2026 | Q2 2026 | -$0.29 | -$0.21 | 0.08 | $7.89 M | $3.16 M |
| 03/26/2026 | Q4 2025 | N/A | -$0.30 | N/A | $2.27 M | $-2,073,000 |
| 09/17/2025 | Q2 2025 | N/A | -$0.25 | N/A | $1.98 M | $4.86 M |
| 04/30/2025 | Q4 2024 | N/A | -$0.30 | N/A | N/A | $276.00 K |
| 09/12/2024 | Q2 2024 | N/A | -$0.31 | N/A | $10.30 M | $12.35 M |
| 04/04/2024 | Q4 2023 | N/A | -$0.12 | N/A | $16.49 M | $16.56 M |
| 06/29/2023 | Q2 2023 | N/A | $0.02 | N/A | N/A | $35.34 M |
| 12/30/2022 | Q4 2022 | N/A | -$0.80 | N/A | N/A | $8.31 M |
| 06/30/2022 | Q2 2022 | N/A | $0.08 | N/A | N/A | $41.27 M |
| 12/31/2021 | Q4 2021 | N/A | -$0.37 | N/A | N/A | $2.79 M |
| 06/29/2021 | Q2 2021 | N/A | -$0.30 | N/A | N/A | $9.32 M |
| 12/31/2020 | Q4 2020 | N/A | -$0.68 | N/A | N/A | $26.99 M |
| 06/30/2020 | Q2 2020 | N/A | -$0.13 | N/A | N/A | $36.75 M |
| 12/31/2019 | Q4 2019 | N/A | -$0.52 | N/A | $21.56 M | $17.39 M |
| 06/30/2019 | Q2 2019 | N/A | $0.21 | N/A | N/A | $51.59 M |
| 12/31/2018 | Q4 2018 | N/A | $0.30 | N/A | N/A | $70.96 M |
| 06/30/2018 | Q2 2018 | N/A | -$0.26 | N/A | N/A | $23.00 M |
| 12/31/2017 | Q4 2017 | N/A | -$0.46 | N/A | N/A | $22.76 M |
| 06/30/2017 | Q2 2017 | N/A | -$0.44 | N/A | N/A | $21.27 M |
| 12/31/2016 | Q4 2016 | N/A | $0.28 | N/A | N/A | $45.04 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Innate Pharma Earnings: FAQ's
In the previous quarter, Innate Pharma (:IPHA) reported $-0.24121 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.29458 by $0.05337.
The conference call for Innate Pharma's latest earnings report can be listened to online.
The conference call transcript for Innate Pharma's latest earnings report can be read online.
Innate Pharma (:IPHA) has a recorded annual revenue of $2.79 M.
Innate Pharma (:IPHA) has a recorded net income of $-49,177,000.Innate Pharma has generated $-0.53 earnings per share over the last four quarters.
Innate Pharma (:IPHA) has a price-to-earnings ratio of -3.05 and price/earnings-to-growth ratio is -0.42.